Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Xencor stock | $38.72

Learn how to easily invest in Xencor stock.

Xencor Inc is a biotechnology business based in the US. Xencor shares (XNCR) are listed on the NASDAQ and all prices are listed in US Dollars. Xencor employs 202 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Xencor

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – XNCR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Xencor stock price (NASDAQ: XNCR)

Use our graph to track the performance of XNCR stocks over time.

Xencor shares at a glance

Information last updated 2021-10-17.
Latest market close$38.72
52-week range$30.12 - $55.33
50-day moving average $34.69
200-day moving average $36.32
Wall St. target price$54.36
PE ratio 95.6965
Dividend yield N/A (0%)
Earnings per share (TTM) $0.40

Buy Xencor shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Xencor stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Xencor price performance over time

Historical closes compared with the close of $38.72 from 2021-10-21

1 week (2021-10-15) 0.65%
1 month (2021-09-23) 12.62%
3 months (2021-07-23) 21.53%
6 months (2021-04-23) -11.15%
1 year (2020-10-22) -1.95%
2 years (2019-10-22) 6.40%
3 years (2018-10-22) 12.04%
5 years (2016-10-21) 81.78%

Is Xencor under- or over-valued?

Valuing Xencor stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Xencor's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Xencor's P/E ratio

Xencor's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 96x. In other words, Xencor shares trade at around 96x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Xencor's EBITDA

Xencor's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $27.5 million.

The EBITDA is a measure of a Xencor's overall financial performance and is widely used to measure a its profitability.

Xencor financials

Revenue TTM $178.6 million
Gross profit TTM $-47,108,000
Return on assets TTM -3.4%
Return on equity TTM 3.86%
Profit margin 13.17%
Book value $11.09
Market capitalisation $2.2 billion

TTM: trailing 12 months

Shorting Xencor shares

There are currently 2.3 million Xencor shares held short by investors – that's known as Xencor's "short interest". This figure is 9% down from 2.5 million last month.

There are a few different ways that this level of interest in shorting Xencor shares can be evaluated.

Xencor's "short interest ratio" (SIR)

Xencor's "short interest ratio" (SIR) is the quantity of Xencor shares currently shorted divided by the average quantity of Xencor shares traded daily (recently around 198348.18024263). Xencor's SIR currently stands at 11.54. In other words for every 100,000 Xencor shares traded daily on the market, roughly 11540 shares are currently held short.

However Xencor's short interest can also be evaluated against the total number of Xencor shares, or, against the total number of tradable Xencor shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xencor's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Xencor shares in existence, roughly 40 shares are currently held short) or 0.0431% of the tradable shares (for every 100,000 tradable Xencor shares, roughly 43 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Xencor.

Find out more about how you can short Xencor stock.

Xencor share dividends

We're not expecting Xencor to pay a dividend over the next 12 months.

Xencor share price volatility

Over the last 12 months, Xencor's shares have ranged in value from as little as $30.12 up to $55.33. A popular way to gauge a stock's volatility is its "beta".

XNCR.US volatility(beta: 0.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xencor's is 0.7079. This would suggest that Xencor's shares are less volatile than average (for this exchange).

Xencor overview

Xencor, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies. It is also developing Tidutamab that is in Phase 1 clinical trial to treat neuroendocrine tumors and gastrointestinal stromal tumors; XmAb564 to treat Autoimmune diseases; XmAb819 for the treatment of renal cell carcinoma; and XmAb306/RO7310729, which is in Phase 1 clinical trial to treat solid tumors. In addition, the company provides Monjuvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome; and AIMab7195 to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It has a collaboration and license agreement with Genentech, MorphoSys AG, Nestlé S. A.

Frequently asked questions

What percentage of Xencor is owned by insiders or institutions?
Currently 1.52% of Xencor shares are held by insiders and 101.254% by institutions.
How many people work for Xencor?
Latest data suggests 202 work at Xencor.
When does the fiscal year end for Xencor?
Xencor's fiscal year ends in December.
Where is Xencor based?
Xencor's address is: 111 West Lemon Avenue, Monrovia, CA, United States, 91016
What is Xencor's ISIN number?
Xencor's international securities identification number is: US98401F1057
What is Xencor's CUSIP number?
Xencor's Committee on Uniform Securities Identification Procedures number is: 98401F105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site